Cytotoxic cd44 antibody immunoconjugates
CA 2443438 A1 · Owner: Sproll, Marlies · Inventors: Patzelt, Erik; Adolf, Guenther; Heider, Karl-Heinz
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present in invention relates to novel conjugates of antibodies with cytotoxic compounds, pharmaceutical compositions containing such conjugates and their use in cancer therapy. In particular the present invention relates , to conjugates of antibodies which are specific for CD44 with maytansinoids preferably with N2'-deacetyl-N2' (3-mercapto-1-oxopropyl)-maytansine (DM1). In a particularly preferred embodiment, the antibody/maytansinoid conjugate may be prepared from a maytansinoid of formula (II) wherein R1 represents H or SR4, wherein R4 represents methyl, ethy linear alkyl, branched alkyl, cyclic , alkyl simple or substituted aryl, or heterocyclic; R2 represents CI or H; R3 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.